Cancer Research Conference 2027 | Sponsor ImmunoMark

The translational bridge

A cancer research conference built around translation, not only discovery

ImmunoMark Summit is a cancer research conference that sits on the bridge between academic discovery and industry development, which is where a supplier’s product moves from a published method into a funded programme. Most suppliers sell at one end or the other; the bridge is where adoption is decided.

Translational teams decide which assays, models, platforms and data tools carry a programme from the lab into the clinic. They are under pressure to pick methods that will survive regulatory scrutiny and scale into trials, and they buy with both scientific and commercial judgement. Organised by Convolign Business Consulting, ImmunoMark runs two parallel streams, Next-Gen Immuno-Oncology and Biomarkers & Companion Diagnostics, and both are programmed around that hand-off.

55–60%of delegates from biotech and pharma

10–15%from academic and research institutions

5–10%clinicians and clinician-scientists

45–50%senior leadership: heads, directors, executives

That mix is the point. A majority from industry means budgets; a meaningful academic share means the group leaders whose methods industry adopts; and a clinician presence means the people who decide whether a biomarker or assay is usable at the bedside. A supplier who meets all three in two days sees the whole adoption path for its product.

Edition comparison

Choosing your edition: the oncology conference 2027 calendar

ImmunoMark runs as a series. Each edition has the same two streams and the same packages, so a supplier can run one plan in more than one market.

	San Diego	London	Boston
Dates	10–11 February 2027	3–4 March 2027	June 2027 (date to be confirmed)
Status	Launch edition	2nd annual	Launch edition
Expected delegates	300+ senior delegates	400+ target; 60% UK & Ireland, 40% rest of Europe	300+
Track record	New edition, same format as London	2026: 300+ delegates, 100+ companies, 15–25 meetings per sponsor	New edition
Translational sessions to note	From Biomarker Discovery to Commercial Success: Translating Innovation into Clinical Practice; Clinical Utility of Predictive Biomarkers in Personalised Oncology	Translational Research: Bridging Academia & Industry; Keynote: Emerging Predictive & Prognostic Biomarkers in IO; C-Further: Pioneering Child-First Cancer Medicines (Lone Friis, LifeArc)	Programme to be announced

The London agenda puts translation front and centre with a dedicated Day 2 session on bridging academia and industry, and London 2026 drew companies such as GSK, Roche, AstraZeneca and Merck alongside academic groups and UK biotechs. San Diego’s programme follows the full innovation journey, from discovery and translational research through clinical development to commercialisation. See the San Diego sponsorship page and the London sponsorship page for edition detail.

Who you will meet

The three groups on the translational path, and what they buy

These profiles come from the edition programmes. Each group buys differently, so plan your meetings and your message for each.

Industry translational teams

Heads and directors of translational medicine, principal scientists and biomarker operations leads at biotech and pharma companies.

Validated assays that will hold up in trials
Outsourced translational and biomarker work
Platforms that scale from discovery to clinical samples

Academic research groups

Principal investigators, group leaders, senior scientists and faculty in tumour immunology, cancer biology, genomics and computational biology.

Reagents, models and instruments for discovery
Collaborative data and early-access programmes
Methods that industry partners will adopt

Clinician-scientists

Translational and clinical biomarker leads, medical oncologists, pathologists and clinical trial investigators.

Tests and workflows usable in pathology and trial units
Evidence of clinical utility
Sample and data handling that fits the clinic

Suppliers already work this way at ImmunoMark. Sponsors at London 2026 described the audience as a combination of people doing fundamental research and clinicians, and research suppliers such as PromoCell, Miltenyi Biotec and Hologic Diagenode took part.

Packages

Which packages fit suppliers to translational cancer research

Packages are the same at every edition, which makes a repeatable plan easy to run in two or three cities. Every tier includes the delegate list with contact details and post-event branding.

Best fit

Gold

A balanced, repeatable package: enough meetings to reach all three buyer groups and a talk slot to present translational data, at a level you can run at more than one edition.

6 pre-scheduled 1:1 meetings
30-minute talk on Day 2, pre-lunch, in your chosen stream
10 x 6 ft booth
6 team passes plus 6 client passes
Half-page brochure advertisement

Platinum

For your priority edition, where you want a Day 1 stage and a larger meeting programme.

10 pre-scheduled 1:1 meetings
30-minute Day 1 talk
Email to registered attendees and attendee list a week before
8 team passes plus 8 client passes

Exclusive 1:1 Meetings

For a second or third edition where you want targeted conversations without a stand.

3, 5, 7 or 10 meetings of 20 minutes
2–4 delegate passes
Drinks reception passes
Wishlist and delegate list

Meetings work the same way everywhere: ten days before each edition you receive the full delegate list with profiles and choose who to meet, and a wishlist flags the people you want to reach beyond your allocation. Each edition closes Day 1 with a networking drinks reception.

Tell us which editions you are weighing and we will send the prospectus for each.

Request the prospectus

Building a series plan

Fitting ImmunoMark into your cancer conferences 2027 budget

A large oncology congress gives reach; a focused oncology conference gives conversations. Most suppliers need both, and the question is where to put the conversation budget.

Customers mostly in Europe

Lead with London. Of the oncology conferences UK suppliers can choose, it combines UK academic groups with a 40% continental European share. Research suppliers should read the London page for research suppliers.

Customers on the US West Coast

Lead with the San Diego launch in February, early in the budget year. The San Diego research ecosystem page covers the local buyer groups.

Transatlantic or IO-led

Run Gold in one city and 1:1 meetings in another, then add Boston in June. IO-heavy suppliers should compare themes on the immuno-oncology summit page.

For a view of where cell and gene therapy and their biomarkers are heading, and what that means for translational suppliers, read our advanced therapies biomarker outlook. Whatever mix you choose, plan each edition backwards from the meetings you want, not from the size of the stand.

What sponsors said

Feedback from London 2026 sponsors

Here is what sponsors told us at our London 2026 launch edition.

We really liked the focus of the event, the topics, the talks, really good opportunity to engage with people, the support we get from you is really great and we appreciate that very much. Based on our experience we would be very interested in also sponsoring the next annual event.

Project Manager

PromoCell GmbH · Sponsor, London 2026

We are always interested in sponsoring interesting conference, based on this years experience, I guess I will manage to get some budget for the next edition.

BD Manager Europe

Secretech · Sponsor, London 2026

Conversations I have had are very high level, the footfalls been great and the kind of research going on around is really life changing. We will be very interested in sponsoring the second annual.

Research Account Manager

Miltenyi Biotec · Sponsor, London 2026

My experience here at Immunomark 2026 has been really great. We benefit from very good logistical organisation. Networking sessions were excellent and we consider Immunomark a strategic conference for the coming years.

Senior Business Development Director Europe

Rouken Bio · Sponsor, London 2026

We got the occasion to discuss customer projects and understand their needs better and how we can help them.

Epigenomics Applications Specialist

Hologic Diagenode · Sponsor, London 2026

The conference has been great so far with strong interactions at the booth and excellent attendance at our talk. We will definitely think about the next edition.

Biopharma Business Development Manager EMEA

Hologic Diagenode · Sponsor, London 2026

Quality of the talks were really nice and the attendee list had experts from biotech pharma field. It was great meeting everyone and we look forward to positive outcomes.

Business Development Executive

HistologiX · Sponsor, London 2026

The talks have been really interesting so far with a great combination of researchers and clinicians. Moderators encouraged excellent discussions.

Product Specialist

HAWK Biosystems · Sponsor, London 2026

Get the prospectus

Frequently asked questions

Which ImmunoMark edition suits a supplier to translational cancer research?

Choose by where your customers are. London (3–4 March 2027) is the 2nd annual edition with a 400+ target, 60% from the UK and Ireland and 40% from the rest of Europe. San Diego (10–11 February 2027) is a launch edition with 300+ senior delegates expected. Boston is a launch edition in June 2027 with 300+ delegates.

How is the audience split between industry and academia?

The prospectus puts 55–60% of delegates in biotech and pharma, 10–15% in academic and research institutions, 5–10% clinicians and about 5% in government, regulatory and industry bodies. By seniority, 45–50% are senior leadership and 20–30% are scientists, principal investigators and technologists.

Are the sponsorship packages the same at every edition?

Yes. Headline, Platinum, Gold, Silver, Exhibitor, Exclusive 1:1 Meetings and the branding packages are offered at every edition with the same inclusions. Every tier includes the delegate list with contact details and post-event branding. Request the prospectus for current availability.

Can we sponsor more than one edition?

Yes. Many suppliers pair a larger package at their priority edition with 1:1 meetings at a second. Because the format and packages are consistent, the same talk, meeting plan and follow-up process can run in each city.

What evidence is there that the format works for suppliers?

At London 2026 the summit drew 300+ delegates from 100+ companies, 70% of them senior decision-makers. The post-show report records 200+ meetings, 15–25 meetings per sponsor and 55+ pre-scheduled 1:1 meetings for title sponsors.

Cancer Research Conference Sponsorship for Translational Suppliers

Get the prospectus and package availability